Tricida, Inc. (TCDA): Price and Financial Metrics


Tricida, Inc. (TCDA): $8.81

-0.19 (-2.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TCDA Stock Price Chart Interactive Chart >

Price chart for TCDA

TCDA Price/Volume Stats

Current price $8.81 52-week high $9.90
Prev. close $9.00 52-week low $3.55
Day low $8.71 Volume 161,700
Day high $9.14 Avg. volume 270,593
50-day MA $8.18 Dividend yield N/A
200-day MA $5.39 Market Cap 444.45M

Tricida, Inc. (TCDA) Company Bio


Tricida, Inc., a late-stage pharmaceutical company, focuses on developing therapeutics to address renal, metabolic, and cardiovascular disease. Its lead product candidate, TRC101, a non-absorbed orally-administered polymer drug that is in Phase III clinical trials used to treat metabolic acidosis in patients with chronic kidney disease. The company was founded in 2013 and is based in South San Francisco, California.


TCDA Latest News Stream


Event/Time News Detail
Loading, please wait...

TCDA Latest Social Stream


Loading social stream, please wait...

View Full TCDA Social Stream

Latest TCDA News From Around the Web

Below are the latest news stories about Tricida Inc that investors may wish to consider to help them evaluate TCDA as an investment opportunity.

Tricida to Present at the 40th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright BIOCONNECT Virtual Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 7:30 am PT / 10:30 am ET. Gerrit Klaerner, Ph.D., Tricida’s Founder, President and CEO, will provide a company overview, business update and progress on the company’s key initiatives. The live presentation will be accessible on the Tricida website at IR.Tricida.com. An archive of the

Yahoo | January 4, 2022

Tricida to Present at the 40th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 am PT / 1:30 pm ET. Gerrit Klaerner, Ph.D., Tricida’s Founder, President and CEO, will provide a company overview, business update and progress on the company’s key initiatives. A live webcast of the presentation will be accessible on the Tricida website at IR.Tricida.com. An ar

Yahoo | December 15, 2021

Do Options Traders Know Something About Tricida (TCDA) Stock We Don't?

Investors need to pay close attention to Tricida (TCDA) stock based on the movements in the options market lately.

Yahoo | December 1, 2021

Why Tricida Stock Is Jumping Today

Shares of Tricida (NASDAQ: TCDA) were jumping 11% higher as of 11:23 a.m. EST on Tuesday. The solid gain came after the company announced that it had entered into definitive agreements to sell stock and warrants that will generate gross proceeds of around $42 million. It's par for the course for drugmakers to raise additional capital through issuing new shares and/or warrants.

Yahoo | November 16, 2021

Tricida Raises $42 Million in Registered Direct Equity Financing

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow chronic kidney disease (CKD) progression in patients with metabolic acidosis and CKD, announced today that it has entered into definitive agreements with certain investors for the purchase and sale of common stock, pre-fun

Yahoo | November 15, 2021

Read More 'TCDA' Stories Here

TCDA Price Returns

1-mo N/A
3-mo 91.94%
6-mo 115.40%
1-year 18.26%
3-year -58.23%
5-year N/A
YTD -7.85%
2021 35.60%
2020 -81.32%
2019 60.05%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6834 seconds.